Omeprazole Active Not Recruiting Phase 1 Trials for Mantle Cell Lymphoma (MCL) / Diffuse Large B-Cell Lymphoma (DLBCL) / Advanced Solid Tumors / Marginal Zone Lymphoma (MZL) / Primary Mediastinal Lymphoma Treatment

Active Not RecruitingTreatment1 IdentifierTitleDrugs
NCT03028103Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients